The advanced electrocardiogram developer, spun out of Stanford University, has set the range for an initial public offering sized at up to $91m.
iRhythm Technologies, a US-based cardiac diagnostics technology spinout of Stanford University, set the terms yesterday for an initial public offering that will give an exit to pharmaceutical firm Novo.
The company will issue 5.35 million shares priced between $13.00 and $15.00, which would place the size of the IPO at $80.3m to $91m. Should the underwriters take up the option to acquire another 800,000 shares the size of the offering could reach almost $105m.
Spun out in 2006, iRhythm…
